Bigtincan Holdings Limited

Equities

BTH

AU000000BTH6

Biotechnology & Medical Research

Market Closed - Australian S.E. 07:10:22 14/06/2024 BST 5-day change 1st Jan Change
0.105 AUD 0.00% Intraday chart for Bigtincan Holdings Limited -25.00% -47.50%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
US Inflation, Policy Announcement Jitters Suppress Appetite for Australian Shares MT
Bigtincan Holdings Says Non-Binding Indicative Offer from Vector Capital Withdrawn; Shares Down 18% MT
Vector Capital Management, L.P. cancelled the acquisition of Bigtincan Holdings Limited. CI
Bigtincan Holdings Receives AU$0.25 Per Share Acquisition Offer from Vector Capital Management MT
Vector Capital Management, L.P. made an offer to acquire Bigtincan Holdings Limited for AUD 150 million. CI
Bigtincan Holdings Limited Announces Executive Changes CI
Bigtincan Holdings Logs AU$30 Million Revenue in Fiscal Q3; Shares Surge 19% MT
Bigtincan Holdings Limited(ASX:BTH) dropped from S&P/ASX All Ordinaries Index CI
Bigtincan Shares Shed 11% as Fiscal H1 Revenue Contracts 1.5%; Loss Narrows MT
Transcript : Bigtincan Holdings Limited, H1 2024 Earnings Call, Feb 27, 2024
Bigtincan Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Transcript : Bigtincan Holdings Limited - Shareholder/Analyst Call
Bigtincan Holdings Limited Provides Earnings Guidance for the Fiscal Year 2024 CI
Bigtincan Holdings Limited Announces Resignation of Farouk Hussein as Non-Executive Director CI
Bigtincan Holdings Limited(ASX:BTH) dropped from S&P Global BMI Index CI
Bigtincan Reportedly Say It Remains in Takeover Talks CI
Bigtincan Holdings Launches Cost Reduction Program MT
Transcript : Bigtincan Holdings Limited, 2023 Earnings Call, Aug 30, 2023
Bigtincan Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Bigtincan to Borrow AU$15 Million to Grow AI Technology MT
Bigtincan Holdings Limited Provides Financial Results Outlook for Fiscal Year 2023 CI
Transcript : Bigtincan Holdings Limited - Special Call
Bigtincan Holdings Limited Launches GenieAI Technology, Delivering Transformational Sales Productivity Gains to Customers CI
Bigtincan Holdings Limited Provides Earnings Guidance for the Year 2023 CI
Transcript : Bigtincan Holdings Limited, H1 2023 Earnings Call, Feb 27, 2023
Chart Bigtincan Holdings Limited
More charts
Beta Pharmaceutical Limited is a Australia-based biopharmaceutical company. The Company is focused on the identification, development and commercialization of products and therapies targeting the chemoprevention and treatment of breast cancer. The Company is working in collaboration with scientists at the College of Pharmacy, University of Louisiana at Monroe in southern the United States of America (ULM) to develop cancer chemopreventive agents using natural phytonutrients, called tocotrienols as treatments for breast cancers. Funded by Beta Pharmaceutical Limited, the applied research programme with ULM includes four laboratories and is known as the Breast Cancer and Health Project, which has been underway.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.105 AUD
Average target price
0.375 AUD
Spread / Average Target
+257.14%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. BTH Stock
  4. News Bigtincan Holdings Limited
  5. Bigtincan Shares Shed 11% as Fiscal H1 Revenue Contracts 1.5%; Loss Narrows
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW